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Abstract
Tumor-associated macrophages (TAMs) invade the tumor stroma in many cancers, yet their role is incompletely
understood. To visualize and better understand these critical cells in tumor progression, we screened a portfolio of
rationally selected, injectable agents to image endogenous TAMs ubiquitously in three different cancer models
(colon carcinoma, lung adenocarcinoma, and soft tissue sarcoma). AMTA680, a functionally derivatized magneto-
fluorescent nanoparticle, labeled a subset of myeloid cells with an “M2” macrophage phenotype, whereas other
neighboring cells, including tumor cells and a variety of other leukocytes, remained unlabeled. We further show
that AMTA680-labeled endogenous TAMs are not altered and can be tracked noninvasively at different resolutions
and using various imaging modalities, e.g., fluorescence molecular tomography, magnetic resonance imaging, and
multiphoton and confocal intravital microscopy. Quantitative assessment of TAM distribution and activity in vivo
identified that these cells cluster in delimited foci within tumors, show relatively low motility, and extend cytoplas-
mic protrusions for prolonged physical interactions with neighboring tumor cells. Noninvasive imaging can also be
used to monitor TAM-depleting regimen quantitatively. Thus, AMTA680 or related cell-targeting agents represent
appropriate injectable vehicles for in vivo analysis of the tumor microenvironment.
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Introduction
Tumor-associated macrophages (TAMs) are bone marrow–derived
mononuclear phagocytes that invade the tumor stroma in many
cancers, participate in tumor invasion, angiogenesis and metastasis
formation [1–5], and can modulate tumor-specific T-cell immunity
[6,7]. The accumulation of TAMs is therefore generally associated
with a poor prognosis [8], whereas their removal in animal models
can lead to tumor regression [9]. Tumor-associated macrophages
rely on migration and cell-cell contact for information transfer, yet
most of our knowledge on the function mediated by these cells
have been obtained ex vivo through inference from static snapshots.
Also, surrogate in vitro culture models do not faithfully reproduce
the behavior of immune cells in tissues [10]. Novel in vivo imaging
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technologies have recently made it possible to quantify and catalog
the behavior and function of some immune cells that control tumor
growth [11]. For example, elegant work on tumor cell invasion in
animal models of breast cancer has revealed that perivascular TAMs
recruit motile tumor cells and promote their exit into blood ves-
sels [3,12]. In vivo studies have also shown that TAMs undergo
long-lasting interactions with tumor-infiltrating lymphocytes [13]
and thus may supply a variety of immunosuppressive signals that
attenuate antitumor T cell activity [14,15]. These and other studies
have used genetically modified mice expressing fluorescent reporters
(e.g., enhanced green fluorescent protein [EGFP]) that can be tracked
with appropriate optical imaging technologies. The genetic reporter
approach is particularly useful for the study of cells at microscopic reso-
lution; however, currently, it does not allow adequate imaging in larger
fields of view (e.g., at mesoscopic and macroscopic scales), at increased
depths (e.g., >600 μm), or in human patients with cancers.
Injectable multimodal imaging agents that are specific for molecular
targets are an attractive alternative because they offer the advantage of
being usable in both experimental animals and humans, they can carry
multiple reporters for imaging at different resolutions and depths (e.g.,
fluorochromes, quantum dots, [super]paramagnetic particles, radio-
nuclides), and they can combine diagnostic and therapeutic interven-
tional capabilities [16–23]. Such agents exist for a small minority of
targets of interest in cancer and are highly suitable for in vitro analysis,
but their in vivo behavior (e.g., target selectivity, biocompatibility) is
generally not fully characterized. Here, we developed and validated in-
jectable imaging agents that can be used to target endogenous TAMs
selectively. Such agents may be valuable for understanding the biology
of these cells and may have important prognostic and therapeutic im-
plications in cancer and other inflammatory diseases.
We previously tested a library of 146 nanoparticles decorated with
different synthetic small molecules [18] and several protease-targeted
optical sensors [24] for their capacity to target macrophages in vitro.
Here, we rationally selected and extensively tested four lead can-
didates for their ability to selectively label TAMs in vivo. Two of these
agents are cross-linked iron oxide (CLIO) magnetofluorescent nano-
particles (CLIO680 and AMTA680) with affinity for TAMs [18].
AMTA680 is decorated with N-terminal glycines and was identified
among a library of modified CLIO nanoparticles with high affinity
for activated macrophages in vitro [18]. The two other agents are
enzyme-targeted optical sensors (ProSense680 and MMPSense680)
that are activated by cathepsins and matrix metalloproteinases, re-
spectively, expressed by TAMs [24,25]. We evaluated these agents
in three animal models: a subcutaneously injected mouse colon car-
cinoma [26] and two genetically inducible mouse models that reca-
pitulate either human lung adenocarcinoma or soft tissue sarcoma.
Mice with conditional mutation in the endogenous Kras gene (LSL-
KrasG12D mice) develop lung adenocarcinoma after intranasal in-
stillation of an adenovirus expressing Cre recombinase [27], whereas
mice with conditional mutations in the endogenous Kras and p53
genes (LSL-KrasG12D;LSL-p53) develop soft tissue sarcoma after
intramuscular adenovirus injections [28]. The technique presented
here profiles the cellular uptake of imaging agents in vivo, identifies
one of them with specificity for a subset of TAMs within the tumor
microenvironment, and demonstrates the efficient detection of endog-
enous cells by means of complementary microscopic, mesoscopic, and
macroscopic imaging approaches. Labeling and imaging of endoge-
nous TAMs allowed us to monitor TAMs–tumor cells interactions
and to topograph TAMs infiltrates in the tumor microenvironment.
Materials and Methods
Animal Models
Three murine tumor models were used for these studies.
1. Lung adenocarcinoma: Mice with conditional mutation in the
endogenous Kras gene (LSL-KrasG12D mice) received intra-
nasal instillation of an adenovirus expressing Cre recombinase
to generate a temporally and spatially restricted model of lung
adenocarcinoma [27].
2. Soft tissue sarcoma: Mice with conditional mutations in the en-
dogenous Kras and p53 genes (LSL-KrasG12D;LSL-p53) re-
ceived intramuscular injections of the adenovirus mentioned
previously to generate a model of soft tissue sarcoma [28].
3. Syngeneic tumor model: Female BALB/c mice, 6 to 8 weeks old,
received 1 × 106 CT26 or CT-26-GFP colon carcinoma cells
subcutaneously into the upper side of the hind paw in 50-μl
saline or intradermally in a dorsal skin window chamber in
20-μl saline as previously described [29].
The Massachusetts General Hospital Subcommittee on Research
Animal Care approved all in vivo protocols and procedures.
Imaging Agents
From a library of 146 nanoparticles decorated with different syn-
thetic small molecules [18] and protease-targeted optical sensors
[24,30], four agents were selected because of their TAMs imaging
potential and because they are close to clinical testing. These agents
are ProSense680, MMPSense680, CLIO680, and AMTA680. All con-
tain the fluorochrome VT680. AMTA680 is a derivative of CLIO680
decorated with N-terminal glycines conferring a negative Z-potential
(ZAMTA = −24.5, ZCLIO = 6.38). We injected 2 nmol of ProSense680
or MMPSense680 (VisEn Medical, Woburn, MA). The probes gener-
ate far-red fluorescence when cleaved by cathepsins or matrix metallo-
proteinases, respectively. We also injected CLIO680 and AMTA680
(12.5-mg iron/kg), which are dextran-coated iron oxide core nanopar-
ticles coupled with VT680. All probes were injected 24 hours before
imaging unless otherwise stated. We also used AngioSense (VisEn
Medical) for visualization of blood vessels, and CLIO, AMTA, and
VT680 NHS ester [29] were used as control agents.
Flow Cytometry
Footpad, lung, and sarcoma tumors were excised and digested for
30 minutes at 37°C in RPMI medium completed with 0.2 mg/ml col-
lagenase IV (Boehringer Mannheim, Indianapolis, IN) and 0.04 mg/ml
DNAse1 (Roche Molecular Biochemicals, Indianapolis, IN). Spleens
were manually homogenized. The digested tumors and the processed
spleens were filtered through a 70-μm cell strainer to obtain single-
cell suspensions and were treated with an ACK buffer (0.15 MNH4Cl,
10 mMKHCO3, 0.1 mMNa2-EDTA, pH 7.3) to lyse red blood cells.
Cells were either labeled with anti–CD11b-APC alone or together
with CD90-PE, B220-PE, CD49b-PE, NK1.1-PE, and Ly-6G-PE
(BD Biosciences, San Jose, CA) for 30 minutes at 4°C as described
[24,31] and analyzed using an LSRII or sorted using FACSAria (both
from BD Biosciences). Excitation and detection of the VT680 fluoro-
chrome used a red helium-neon 635 nm laser and a filter combination
of 685/LP and a 695/40BP. For comparison of fluorescence intensity
measurements across studies, we calibrated the flow cytometer with
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RFP-30-5A rainbow particles (Spherotech, Lake Forest, IL) before each
acquisition. Aliquots of 50,000 cells were sorted and morphologically
characterized after staining with HEMA 3 (Biochemical Sciences,
Bridgeport, NJ). Trypan blue exclusion staining was used to estimate
the number of living cells.
Microscopic Imaging
We used a dorsal skin fold chamber model [29] for in vivo moni-
toring of AMTA680 uptake at microscopic resolution. After 7 days
of tumor growth, AngioSense-584 and AMTA680 were administered
intravenously, and mice were analyzed immediately by multiphoton
microscopy (Prairie Technologies ULTIMA IV equipped with a 20×/
0.95 NA objective lens and two Spectra-Physics Ti-S laser). For fluo-
rescence excitation, the coaxially aligned beams of a DeepSee and a
MaiTai HP Ti:Sapphire laser (both Spectra-Physics/Newport, Moun-
tain View, CA) were individually tuned to achieve optimal excitation
of all fluorochromes of the particular experiment. Typically, the exci-
tation wavelengths used were 845 and 920 nm. Settings were opti-
mal for dual observation of AMTA680 and tumor cells (EGFP) as
described previously [29]. Stacks of 10 optical sections were acquired
every 30 seconds for 4 hours to provide image volumes of 50 μm
in depth and 500 μm in width and length for four-dimensional re-
cordings of AMTA680 uptake. Some mice were also imaged by con-
focal microscopy using a Biorad Radiance 2100 multichannel laser
scanning microscope (Bio-Rad, Hercules, CA) installed on a Nikon
Eclipse E600 microscope (Nikon Instruments, Melville, NY) with
a 20× water immersion objective (Nikon Fluor 20×/0.5 NA) and
the Lasersharp 2000 software. Individual channels were scanned line
by line separately to avoid bleed through between channels. A four-
line Argon laser (457, 477, 488, and 514 nm) and a red laser diode
(637 nm) were used for EGFP and AMTA680 excitation. The 560
DCLP and 650 DCLP dichroic mirrors and HQ515/30 (EGFP) and
HQ660LP (VT680) emission filters were used to collect light from
different channels. Four-dimensional recording were made by accu-
mulating z-stacks of 11 images at 4-μm intervals along the z-axis at
15-second intervals for 45 minutes. z-Stacks were projected into a
single plane using maximum-intensity projection for the final movie.
Images are 256 × 256 pixels, and movies are shown at 20 images/sec,
which corresponds to 300 times faster speed.
Macroscopic Imaging
Mice received a nonfluorescent/reduced manganese diet (Harlan-
Teklad, Indianapolis, IN) 5 days before imaging and were shaved and
depilated. Imaging was performed 24 hours after probe administration,
unless otherwise stated. Fluorescence molecular tomography (FMT)
used an FMT or an FMT2500 system (VisEn Medical) for excitation
and emission scans at 670 and 700 nm, respectively. Anesthetized mice
were maintained in a fixed position within an imaging cartridge to
allow point-based image fusion. Reconstruction of three-dimensional
maps of fluorochromes was done as described [32], and data were ex-
pressed as mean fluorescent concentration. Magnetic resonance imag-
ing (MRI) used a BioSpin 7T (Bruker BioSpin, Billerica, MA) with
T2-weighted RARE sequence, echo time = 48 milliseconds, repetition
time = 2000 milliseconds, and number of averages = 8. Eighteen coro-
nal images were acquired with a matrix size of 192 × 256 and 0.195 ×
0.260 × 1–mm voxels. Baseline control images for MRI and FMTwere
acquired before AMTA680 injection. The FMT-MRI image fusion
used the Tudor DICOM ImageJ plugin (http://imagejdocu.tudor.lu/
imagej-documentation-wiki/plugins/the-tudor-dicom-toolkit) to pro-
duce reflectance-fluorescence fused FMT DICOM images, dicomlib
(http://dicomlib.swri.ca/dicomlib.html) to generate adequate headers,
and Osirix 3 (The Osirix Foundation, Geneva, Switzerland) for point-
based registrations. Quantification of cell motility and interaction time
was calculated as described [33].
Immunohistochemistry
CT26 tumors excised on day 7 were frozen in OCT compound
(Sakura Finetek, Torrance, CA) and sectioned in 5-μm slices. Adja-
cent sections were incubated with 0.3% hydrogen peroxide to inhibit
endogenous peroxidase activity and incubated with rat antimouse
CD11b (BD Pharmingen, San Diego, CA) or NIMP-R14 (Santa
Cruz Biotechnology, Inc, Santa Cruz, CA) antibody. Sections were
washed with PBS, labeled with biotinylated antirat immunoglobulin
G antibody (Vector Laboratories, Inc, Burlingame, CA) and with an
avidin-peroxidase complex (Vectastain ABC Kit; Vector Laboratories).
Reactions were visualized with 3-amino-9-ethyl carbazole substrate
(AEC; Sigma Chemical, Co, St. Louis, MO). Sections were counter-
stained with Mayer’s hematoxylin solution (Sigma) and mounted.
Images were captured on a digital camera (Nikon DXM1200-F;
Nikon Inc) with ACT-1 imaging version 2.63 software. Fluorescence
microscopy visualized simultaneously 1) AMTA680, 2) NIMP-R14+
cells or CD11b+ cells labeled with fluorescein-conjugated streptavidin
(GE Healthcare Bio-Sciences, Piscataway, NJ), and 3) 4′-6′-diamidino-
2-phenylindole (DAPI; Vector Laboratories). Images were captured and
processed with an epifluorescence microscope (Eclipse 80i; Nikon In-
struments) equippedwith a cooledCCDcamera (Cascade; Photometrics,
Tucson, AZ).
Real-time Polymerase Chain Reaction
RNA extraction was performed using the RNAeasy Kit (Qiagen,
Valencia, CA) and with flow-sorted cells from spleen or tumor on day
14 after tumor implantation or from spleen of tumor-free mice. Comple-
mentary DNA preparation and quantitative polymerase chain reactions
were performed using TaqMan gene expression assays according to the
manufacturer’s protocol (Applied Biosystems, Foster City, CA).Mean nor-
malized gene expression (“deltaCt”) was calculated from two independent
experiments using 18s RNA as a reference gene and expression values for
TAMs were set to 1. Assays used interleukin 4 (IL-4) Mm00445259_
m1, IL-10 Mm00439616_m1, Tie2 Mm00443242_m1, VEGFa
Mm00437304_m1, and EGF Mm00438696_m1.
Statistics
Experiments were performed at least in triplicate (except for sarcoma)
and representative data are shown. Results were tested for statistical
significance using Student’s t test withWelch’s correction when two vari-
ables were measured, whereas three variables or more were tested with
one-way analysis of variance with subsequent Tukey tests of each pairs
with GraphPad Prism version 4.0a software (Graph Pad Software, La
Jolla, CA).
Results
A Screening Method for Evaluating Injectable Imaging Agents
From an initial library of ∼150 injectable imaging agents [18,24,30],
we rationally selected ProSense, MMPSense, CLIO, and AMTA based
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on their capacity to target macrophages in vitro and tested their cellu-
lar uptake in vivo in BALB/c mice bearing carcinoma-derived CT26-
GFP tumor cells. All agents contained the far-red fluorochrome VT680
[29]. We administered each agent intravenously in separate mice 6 days
after tumor inoculation and used flow cytometry on day 7 to analyze
single-cell suspensions obtained from excised tumors. Myeloid cells
were defined as CD11b+GFP−, tumor cells as CD11b−GFP+, and
“other” cells as CD11b−GFP− (Figure 1A). Microscopic examination
of flow-sorted cell subsets confirmed their morphological features:
CD11b+ cells showed heterogeneous myeloid-like phenotypes typ-
ical of neutrophils or TAMs; GFP+ cells showed large, polymorphic,
and sometimes polynucleated attributes distinguishing tumor cells;
CD11b−GFP− cells consisted mainly of smaller cells with round nuclei
suggesting lymphocytes (Figure 1B). Among the four agents tested,
AMTA680 was the only one with specificity for myeloid cells versus
tumor cells (P < .001). ProSense680 and CLIO680 showed higher
uptake in tumor cells than in myeloid cells (P < .05 and P < .01, re-
spectively), whereas we detected similar uptake of MMPSense680 by
tumor cells and myeloid cells, although we noted highly variable fluo-
rescence intensity in tumor cells (Figure 1C). Nonfluorescent nanopar-
ticles (CLIO and AMTA) served as negative controls. The NHS-ester
VT680 alone (i.e., fluorochrome not attached to a nanoparticle) served
as an additional control (Figure 1C), as it is known to covalently label
virtually all cells nonspecifically [29]. A pie chart representation of the
percentage of each probe-positive population shows the difference of
cellular uptake pattern for AMTA680 compared with the other imaging
Figure 1. In vivo targeting of endogenous tumor-associated myeloid cells with AMTA680. (A) Flow cytometric analysis of cell suspen-
sions obtained from excised tumors and stained with anti-CD11b mAb (tumor cells stably express EGFP) identifies myeloid cells (i),
tumor cells (ii), and “other” cells (iii), n = 9. (B) Morphological analysis of sorted cells. (C) Analysis of tumor cell suspensions 24 hours
after intravenous administration of “control” (CLIO, AMTA, VT680) or “targeting” agents (ProSense680, MMPSense680, CLIO680, and
AMTA680). Each histogram shows a representative example of the fluorescence intensity (uptake) of each agent for each cell type.
Figures in the upper right of the histograms show the percentage (mean ± SEM) of cells labeled with the agent when compared with
the corresponding cells in mice that did not receive any agent. All agents but AMTA680: n = 3; AMTA680: n= 27. (D) Distribution of the
targeting agents into different cell types that are present in the tumor environment. The analysis shows the specificity of AMTA680 (but
not of the other agents) for tumor-associated myeloid cells.
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agents (Figure 1D). Our data also indicate that AMTA680 is biocom-
patible because myeloid cells in mice injected with the agent remained
viable, in same numbers, and retained their forward and side scatter
profiles and overall surface phenotype (Figure W1). Similar profiling
in genetically induced lung adenocarcinoma and soft tissue sarcoma
confirmed the specificity of AMTA680 for myeloid cells (Figure 2E).
AMTA680 also labels macrophages in tumor-free tissues, e.g., the
spleen (Figure W2).
Figure 2. AMTA680 preferentially labels TAMs with an “M2-like” phenotype. Immunofluorescence analysis of frozen sections from non-
fluorescent CT26 tumors labeled with anti-CD11b (A) or NIMP-R14 (B) mAb. DAPI is shown in blue. During image acquisition, the signal
integration times required to detect AMTA680 in (B) were an order of magnitude lower than in (A) suggesting that the few AMTA680-
positive neutrophils contain less AMTA680 than TAMs, n = 3. (C) Flow cytometry analysis of cell suspensions of excised tumors iden-
tifies neutrophils (i), TAMs (ii), and other cells (iii). (D) Morphological analysis of sorted cells, n = 3. (E) Percentage of different cell types
labeled with AMTA680 24 hours after administration of the agent in mice with subcutaneous CT26 (n = 4), lung carcinoma (n = 3), or
soft tissue sarcoma (n = 1). Mice with subcutaneous CT26 were also tested after 4 hours (n = 4). (F) Surface phenotype of AMTA680+
and AMTA680− TAMs obtained from CT26 tumors and analyzed by flow cytometry 24 hours after administration of the agent. *P< .005,
**P < .0005, n = 3.
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AMTA680 Labels TAMs with an “M2” Phenotype
The screening described above identified AMTA680 as a myeloid
cell–targeting agent. Histological analysis of CT26 tumor tissue sec-
tions confirmed that AMTA680 accumulates in CD11b+ myeloid
cells but not in tumor cells (Figure 2A) and further identified that
CD11b+ NIMP-R1+ neutrophils do not accumulate the imaging agent
to a significant amount (Figure 2B). Control experiments included
frozen sections frommice that did not receive AMTA680 and unstained
Figure 3.Microscopic imaging of TAMs behavior. (A) Time-course analysis of extravasation and cellular uptake of AMTA680. CT44-GFP
tumor-bearing mice received intravenous injection of a blood pool agent (AngioSense) to delineate vessels (blue, left panel) and
AMTA680 (red, adjacent panels). Multiphoton microscopy images of the same tumor region were recorded every hour. Tumor cells
are also shown (green). (B and C) Change in the percentage of AMTA680 fluorescence in blood vessels (B) and in the number of
AMTA680-labeled extravascular objects (C) over time. (D) Overview of a TAMs-rich region labeled with AMTA680 and recorded 4 hours
after injection. (E) Instantaneous velocity of tumor cells, TAMs, and tumor antigen–specific CTLs in the tumor microenvironment. Cyto-
toxic T lymphocyte specific for the HA antigen (that is expressed by CT44-GFP tumors) were stimulated in vitrowith cognate peptide and
IL-2 and injected intravenously as previously described [13]. Tumors: n= 11, TAMs: n = 109, CTLs: n = 91. (F) Instantaneous velocity of
cells plotted in 1-μm/min bins. (G) Physical interactions between TAMs (red) and tumor cells (green). (H) Long-lasting physical interac-
tions between TAMs and tumor cells (n = 8) in comparison to the ones observed between CTLs and tumor cells (n = 11).
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frozen sections (data not shown). To quantify precisely the dis-
tribution of AMTA680 within various myeloid cells, we used a flow
cytometry approach (Figure 2C) previously validated for simultaneous
analysis of neutrophils (CD11b+ (B220/CD90/DX5/NK1.1/Ly-6G)hi
cells) versus macrophages and dendritic cells (CD11b+ (B220/CD90/
DX5/NK1.1/Ly-6G)lo cells) [24]. Microscopic examination of flow-
sorted cell subsets confirmed the morphological features of neutrophils
and TAMs, whereas the “other cells” were predominantly lymphocytes
(Figure 2D). Analysis by flow cytometry revealed that AMTA680
accumulates much more efficiently in TAMs than in lymphocytes
(P < .001) and neutrophils (P < .001). AMTA680 had accumulated
in TAMs at 4 and 24 hours after injection and in all models tested
(e. g., CT26 tumors as well as genetically induced lung adeno-
carcinoma and soft tissue sarcoma; Figures 2E and W3). Immu-
nofluorescence analysis in the last two models also confirmed the
specificity of AMTA680 for TAMs but not for tumor cells (Figure 4E
for soft tissue sarcoma, and data not shown for lung adenocarci-
noma). Ex vivo analysis of TAMs purified from implanted CT26
tumors showed selective AMTA680 labeling of a subset of TAMs
with a F4/80hi I-Ab
hi CD14lo phenotype, whereas AMTA680− cells
Figure 4. Macroscopic imaging of TAMs distribution. A mouse with soft tissue sarcoma in the left crural muscle received AMTA680
intravenously and was analyzed 24 hours later with the following imaging modalities: (A–C) FMT, MRI, and FMT-MRI fusion. (A) Three-
dimensional virtual rendering of TAMs using FMT-MRI fusion. The color-coded optical images use advanced algorithms [32] to recon-
struct and quantitate three-dimensional maps of AMTA680. (B) Different sections of T2-weighted MRIs generated by the iron oxide
superparamagnetic core of AMTA680. (C) Corresponding FMT-MRI fused sections. (D) Hematoxylin/eosin (H&E) and anti-CD11b staining
in an AMTA680 rich region of the tumor as identified by MRI (and FMT). (E) Immunofluorescence analysis for colocalization of AMTA680+
and CD11b+ cells.
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were mostly F4/80lo I-Ab
lo CD14− (Figure 2F ). In addition, the
labeled cells were mostly CD34− and CD11c− and thus contained
neither stem cells nor dendritic cells. The TAMs also showed in-
creased messenger RNA levels of proangiogenic (Tie-2, vascular en-
dothelial growth factor [VEGF ], endothelial growth factor [EGF ])
and immunosuppressive (IL-4, IL-10) genes, when compared with
splenic monocytes purified from non–tumor- or tumor-bearing mice
(Figure W4). We obtained comparable results for TAMs purified from
mice with lung adenocarcinoma (data not shown). Thus, AMTA680-
labeled cells represent mostly F4/80hi “M2-like” tissue macrophages
but not “M1” macrophages or more immature myeloid-derived sup-
pressor cells [1].
Microscopic In Vivo Imaging of TAMs
Having established that AMTA680 selectively labels endogenous
TAMs, we set out in situ imaging approaches to study these cells
in their native environment. Initially, we used multiphoton and con-
focal intravital microscopy to image the tumor microenvironment at
different time points as a way to determine the distribution and cel-
lular uptake of the agent over time. This involved surgical implan-
tation in the dorsum of the animal of a tumor-window chamber
containing CT26-GFP tumor cells [29], followed on day 7 by intra-
venous injection of AMTA680 and a blood pool agent. Immediately
on intravenous injection, AMTA680 distributed in the tumor vascu-
lature (Figure 3A), whereas within 4 hours, a significant fraction of
the agent had spread into the tumor parenchyma (Figure 3B) and
integrated in the cytoplasm of single cells (Figure 3, C and D). We
could detect AMTA680-labeled TAMs efficiently by both multi-
photon and confocal microscopy when using appropriate excitation
and detection wavelengths (Materials and Methods). Next, we per-
formed time-lapse intravital confocal microscopy to derive quantita-
tive parameters of TAMs migration and their physical interactions
with surrounding cellular partners. Measures of instantaneous ve-
locities of cell centroids revealed that both tumor cells and TAMs
are relatively immotile (Figure 3, E and F ). We compared the veloc-
ity of endogenous TAMs to the one of HA-specific effector cytotoxic
T lymphocytes (CTLs) that were also recruited to the tumor stroma
and confirmed that CTLs are typically faster, as reported previously
[10,13,34]. We also found that stationary TAMs polarize and present
cytoplasmic protrusions that physically interact with neighboring
tumor cells for extended periods (typically >30 minutes; Figure 3,
G and H , see also Video W1).
Macroscopic In Vivo Imaging of TAMs
We then tested whether mesoscopic and macroscopic imag-
ing modalities, e.g., FMT, MRI, and FMT-MRI fusion imaging, al-
low to assess the in vivo distribution of AMTA680-labeled TAMs
at the whole tumor (or body) level. To this end, we used a LSL-
KrasG12D-p53−/− mouse ∼25 weeks after initiation of soft tissue sar-
coma in the left crural muscle [28] and imaged the mouse 24 hours
after administration of AMTA680. Fluorescence molecular tomogra-
phy allowed us to reconstruct and quantitate three-dimensional maps
of AMTA680 and to demonstrate well-delimited signal foci within
the tumor (Figure 4A). Magnetic resonance imaging also identified
submillimeter foci of hyposignal (black) on T2-weighted images
generated by the iron oxide superparamagnetic core of AMTA680
(Figure 4B and Video W2). Point-based fusion of FMT and MRI
data sets revealed colocalization of the signals obtained from both
modalities (Figure 4C ).
Next we performed hematoxylin-eosin and CD11b staining in a
section of the tumor matching the AMTA680 signal observed by
FMT-MRI. The overall morphology of the lesion and presence of
CD11b+ cells confirmed the presence of a dense infiltrate of myeloid
cells where AMTA680 signal was detected (Figure 4D). Immunoflu-
orescence analysis demonstrated further that AMTA680 accumulated
selectively in the myeloid cell–rich regions (Figure 4E ). Thus, the
combination of AMTA680 with whole-body noninvasive imaging
techniques such as FMT and MRI permits to assess the distribution
of AMTA680-labeled TAMs noninvasively and in three dimensions
in vivo. These macroscopic approaches for analysis of large fields of
view and deep in tissue complement single-cell confocal and multi-
photon microscopy techniques.
In Vivo Imaging of Anti-TAMs Treatment
Imaging of TAMs can have important prognostic and therapeutic
implications [3,35]. In addition, targeting TAMs is a possible strat-
egy against cancer, and tools to measure the efficiency of TAMs
depletion in vivo would be useful. Here, we tested the ability of
Figure 5. In vivo imaging of anti-TAMs treatment. (A) In vivo FMT imaging of AMTA680-derived signal from the tumor site of CT26 tumor-
bearing mice that received Clo-Lip on day 6 (red) or not (blue). All mice received AMTA680 intravenously on day 6 and were imaged by
FMT on day 7. Clo-Lip–treated mice: n = 5, control mice: n = 4. (B) Positive and linear relationship between FMT-based AMTA680-
derived signal and the number of CD11b+ cells retrieved from excised tumors and analyzed by flow cytometry.
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AMTA680 and FMT to assess the depletion of endogenous TAMs in
mice that received 0.1 ml of clodronate-loaded liposomes (Clo-Lip).
CT26 tumor-bearing mice received Clo-Lip and AMTA680 on day 6
and were analyzed by FMT on day 7. Flow cytometry analysis re-
vealed that treatment with Clo-Lip reduced the number of CD11b+
cells retrieved from the tumor site. Noninvasive FMT imaging also
showed reduced TAMs-associated AMTA680 activity in lesions
(Figure 5A and Video W3), and the number of retrieved CD11b+ cells
positively and linearly correlated with in vivo AMTA680 activity
(Figure 5B: blue dots, mice untreated; red dots, mice treated with
Clo-Lip). Thus, FMT can noninvasively inform on quantitative altera-
tions of TAMs populations over time.
Discussion
Understanding the function and activity of endogenous immune
cells within complex biological systems necessitates the development
of in vivo imaging technologies that are cell-specific and quantitative.
In this study, we set up a screening method of injectable imaging
agents to assess cellular specificity and to quantify cellular uptake.
We show that AMTA680, a surface-tuned magnetofluorescent nano-
particle, labels endogenous TAMs selectively and permits to track
these cells in their native microenvironment. AMTA680 incorporates
two reporter tags: a fluorescent dye for optical imaging and a super-
paramagnetic core for MRI. The VT680 fluorochrome emits at a
far-red wavelength where autofluorescence and tissue absorbance
are minimal and thus allows imaging in deep tissues. In addition,
VT680 is adequate for multiscopic imaging because single-cell and
whole-body information can be integrated from the same animal
by intravital microscopy and FMT, respectively. The combination
of microscopic and macroscopic imaging offers the possibility to
evaluate cellular activity and biodistribution quantitatively and si-
multaneously. Such advances should foster the identification of novel
biomarkers that, when used together, will facilitate a systems-based
understanding of tumor-related cellular and molecular events.
Here, we have focused on TAMs because these immune cells are
recruited to most tumors and are involved in crucial processes during
tumor development. We have found that AMTA680 preferentially
targets “M2-like” TAMs, which express high levels of F4/80 [1]
and VEGF [24]. Together with the overexpression of the endothelial
tyrosine kinase Tie-2 [36], these markers indicate previously de-
scribed cells that have a profound influence on tumor angiogenesis
[1,37]. Using MRI or FMT imaging, we identified that labeled
TAMs mainly cluster in delimited foci within tumors and mostly
in peripheral regions that are rich in newly formed blood vessels (data
not shown). On the basis of their relatively low motility, these TAMs
are likely confined to their microenvironment. Tumor-associated
macrophages are also known to present antigens to T cells and secrete
factors that suppress neighboring T cells. Interestingly, the latter
cells, as shown here and in previous studies, have significantly higher
motility and infiltrate the tumor from the periphery to the center
[10,13,34,38]. It remains to be determined whether peripheral
T cells, en route to the center of the tumor, interact with these TAMs
and receive the immunosuppressive signals. At least, the TAMs un-
dergo prolonged physical interactions with neighboring tumor cells,
mostly through the extension of cytoplasmic protrusions. The quality
of signals that are delivered through cell-cell interactions in vivo
needs to be clarified, but this will require the generation of sophisti-
cated imaging systems that can monitor fluorescence-based molecular
reporters that are expressed at physiological levels.
Injectable imaging agents are now starting to uncover molecular
and cellular processes in vivo. The development of agents with prop-
erties similar to those of AMTA680 and that are approved for injec-
tion into patients would allow in vivo noninvasive monitoring of the
activity and location of biological indicators. The approach would be
useful to diagnose tumor progression and to follow responses to ther-
apeutic drugs. Tissue biopsies or blood samples could also be used to
evaluate cell-targeting agents in patients. Therefore, the technology
presented here is transposable to a variety of experimental approaches
and potentially offers clinical translatability.
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Figure W1. Biocompatibility of AMTA680. (A) CT26 tumor-bearing
mice that were injected or not with AMTA680 were compared
24 hours later for the total number of CD11b+ cells retrieved from
tumors (left panels), and CD11b+ cells were analyzed for propidium
iodide uptake and forward and side scatters (right panels); n.s. in-
dicates not significant, n = 3. (B) TAMs cells retrieved from CT26
tumor-bearing mice that were injected or not with AMTA680 were
compared 24 hours later for their cell surface phenotype; n.s. indi-
cates not significant, n = 3.
Figure W2. Labeling of monocytes/macrophages by AMTA680 in
tumor-free spleen. CT26 tumor-bearing mice (n = 4) as well as
genetically induced lung adenocarcinoma (n = 3) and soft tissue
sarcoma (n = 1) were injected with AMTA680. Spleens were col-
lected 24 hours later and analyzed by flow cytometry. The graphs
show the percentage of neutrophils, monocytes/Mø, and other
cells that are AMTA680+.
Figure W4. “M2” phenotype of TAMs. Relative messenger RNA
expression in sorted monocytes/macrophages obtained from the
spleen of tumor-free mice (“−”) or from the spleen or tumor of
CT26 tumor-bearing mice (“+”). Expression values for TAMs (i.e.,
within tumors) were set to 1, n = 4.
Figure W3. Selectivity of AMTA680 for TAMs but no other tumor
cells in the tumor microenvironment. Mean fluorescence intensity
(MFI) of different cell types 24 hours after administration of
AMTA680 in mice with subcutaneous CT26 (n = 4), lung carci-
noma (n = 3), or soft tissue sarcoma (n = 1). Mice with subcuta-
neous CT26 were also tested after 4 hours (n = 4). Values were
normalized to 1 for TAMs.
Video W1. Microscopic imaging of TAM behavior. Time lapse re-
cording of AMTA680-labeled TAM (red) physically interacting with
tumor cells (green). Time, 45 minutes. Scale bar, 10 μm.
Video W2. Macroscopic imaging of TAM distribution. Three-
dimensional virtual rendering of AMTA680-labeled TAM using FMT-
MRI fusion imaging. The color-coded three-dimensional FMT image
uses advanced algorithms [32] to reconstruct and quantitate three-
dimensional maps of AMTA680 and is fused to T2-weighted MRIs
generated by the iron oxide superparamagnetic core of AMTA680.
Video W3. In vivo imaging of anti-TAM treatment. Three-dimensional FMT acquisition data sets show image reconstruction of footpads
in four groups of mice: CT26 tumor-bearing mice and CT26 tumor-bearing mice that received Clo-Lip on day 6 and two controls that
are mice without tumors or mice that did not receive AMTA680. With the exception of the last group, all mice received AMTA680
intravenously on day 6 and were imaged by FMT on day 7.
